Monday, 15 April 2024

 

 

LATEST NEWS "Don't Miss the SUPERHIT Romantic JODI of Satinder Sartaaj and Neeru Bajwa as Satta and Seero in 'Shayar' Mann holds a road show in favour of AAP candidate of Sonitpur Lok Sabha constituency of Assam Baisakhi Festival: Lt Governor pays obeisance at the Gurudwara Sahib Abtal, Ramgarh Samba Gauri Khan Net Worth 2024 | Know The Income Of Shah Rukh Khan’s Wife Governor Shiv Pratap Shukla honored High Flyers of HP Lt Governor Manoj Sinha pays tributes to General Zorawar Singh on his Birth Anniversary Malaika Arora & Narifirst Aikta Sharma present the Jewel of India Trophy to Dr. Rupinderkaur Khera & Eesha Agarwal Zee Punjabi Stars KP Singh and Isha Kaloya Shine as Guests at Times Food and Nightlife Awards 2024 IPL 2024: PBKS vs RR Match Updates And Playing 11 Predictions LPU secures top spots in QS World University Rankings by Subjects-2024 Karan Johar Net Worth 2024: Know The Wealth of Bollywood's Iconic Producer Indus Public School students presented a colourful cultural programme and visited field on Baisakhi Apurva Padgaonkar Net Worth [April 2024] | 5 Dariya News 12 Best Gurmeet Kaur Web Series List 2024 Updated Ashmah International School celebrated Baisakhi with pomp and show in traditional manner Kidzee Bela Celebrates Baisakhi Festival with Traditional Fervor Colourful function marks Baisakhi at RBU EVs Would become Cheaper, more Powerful, and Safer PEC Students participated in “Bharat SaaS Yatra”, celebrating the rise of SaaS Industries Campaigning for AAP candidates Chief Minister Bhagwant Mann appeals to the people of Assam: bring change in Assam by pressing the number 1 button of 'jharoo' DC Sakshi Sawhney urges residents to vote for better future of coming generations; takes part in 'Vaisakhi celebrations' by Indian Red Cross Society

 

Pfizer's Paxlovid antiviral drug does not reduce risk of long Covid: Study

Covid 19 India
Listen to this article

Web Admin

Web Admin

5 Dariya News

New York , 05 Jan 2024

US pharma giant Pfizer's antiviral drug Paxlovid (Nirmatrelvir-ritonavir) does not reduce the risk of developing long Covid for vaccinated, non-hospitalised individuals, according to a study.A team of researchers from Univesity of California San Francisco (UCSF) revealed that among Paxlovid users, a higher proportion of individuals with acute symptoms rebound and test-positivity than previously reported.

The findings appeared in the Journal of Medical Virology.Paxlovid treatment for acute Covid-19 has been shown to be effective for high-risk unvaccinated individuals. But the effect of the treatment on long Covid risk, including whether it protects vaccinated people from getting long Covid, has been less clear.

To explore, the team selected a group of vaccinated people who had reported their first positive test for Covid-19 between March and August of 2022 and who were not hospitalised.In December 2022, the two groups reported similar conditions. About 16 per cent of those treated with Paxlovid had long Covid symptoms compared to 14 per cent of those who were not treated with the medication.

Commonly reported symptoms included fatigue, shortness of breath, confusion, headache, and altered taste and smell.Those who took Paxlovid and then went on to develop long Covid reported as many long Covid symptoms as those who were not treated with Paxlovid.

A small percentage of people developed severe long-term Covid, and those who had received Paxlovid were just as likely to have severe long-term Covid symptoms as those who did not.Among individuals who experienced symptomatic improvement during Paxlovid treatment, 21 per cent reported rebound symptoms.

And among those with rebound symptoms, 10.8 per cent reported one or more long Covid symptoms compared to 8.3 per cent without rebound symptoms.For participants who repeated antigen testing after testing negative and completing treatment, 25.7 per cent reported rebound test positivity. In total, 26.1 per cent reported rebound symptoms or test positivity.

"We found a higher proportion with clinical rebound than previously reported but did not identify an effect of post-treatment rebound on long Covid symptoms," said Matthew Durstenfeld, a cardiologist and UCSF assistant professor of Medicine.

"Our finding that Paxlovid treatment during acute infection is not associated with lower odds of long Covid surprised us, but it is consistent with two other rigorously conducted studies finding no difference in post-Covid conditions between 4 and 6 months after infection."

The researchers, however, noted that the study may have been impacted by limitations arising from its observational nature with researchers relying on patient self-reporting of treatment and long Covid symptoms.

 

Tags: Coronavirus , Current Covid Symptoms , Covid , Covid 19 Vaccine , Covid Symptoms , Covid Cases In India In Last 24 Hours Today , Present Situation Of Covid 19 In India , Today Corona Cases In India Last 24 Hours , Covid Cases In India Today , Covid New Variant , Covid JN1 Variant , JN1 Variant , JN1 Variant Covid , JN1

 

 

related news

 

 

 

Photo Gallery

 

 

Video Gallery

 

 

5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2024 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD